Emerging treatments
Novel therapies
An increased understanding of the pathogenesis of Burkholderia pseudomallei and Burkholderia mallei in recent years has led to the identification of promising novel biological treatments for melioidosis and glanders. These treatments include Fabl enoyl-ACP reductase inhibitors and protein synthesis inhibitors.[94] GC-072, a potent oral 4-oxoquinolizine antibiotic, has demonstrated in vitro potency against drug-resistant strains of B pseudomallei, and is also active against B mallei.[95]
Use of this content is subject to our disclaimer